Sweis RF - Search Results

1

The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.

Hines JB, Kacew AJ, Sweis RF. Hines JB, et al. Among authors: sweis rf. Curr Oncol Rep. 2023 Mar;25(3):189-199. doi: 10.1007/s11912-023-01361-0. Epub 2023 Jan 27. Curr Oncol Rep. 2023. PMID: 36705879 Free PMC article. Review.

2

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.

Sweis RF, Galsky MD. Sweis RF, et al. Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9. Urol Oncol. 2016. PMID: 27836246 Free PMC article. Review.

3

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.

Kacew A, Sweis RF. Kacew A, et al. Among authors: sweis rf. Front Immunol. 2020 Nov 5;11:575258. doi: 10.3389/fimmu.2020.575258. eCollection 2020. Front Immunol. 2020. PMID: 33224141 Free PMC article. Review.

4

Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival.

Richard G, De Groot AS, Steinberg GD, Garcia TI, Kacew A, Ardito M, Martin WD, Berdugo G, Princiotta MF, Balar AV, Sweis RF. Richard G, et al. Among authors: sweis rf. Sci Rep. 2021 May 11;11(1):9983. doi: 10.1038/s41598-021-89016-7. Sci Rep. 2021. PMID: 33976291 Free PMC article.

5

Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms.

Wang Y, Bergman DR, Trujillo E, Pearson AT, Sweis RF, Jackson TL. Wang Y, et al. Among authors: sweis rf. Sci Rep. 2023 Dec 18;13(1):22541. doi: 10.1038/s41598-023-49467-6. Sci Rep. 2023. PMID: 38110479 Free PMC article.

6

STING activators in cancer care.

Sweis RF. Sweis RF. Clin Adv Hematol Oncol. 2024 Sep;22(7):331-333. Clin Adv Hematol Oncol. 2024. PMID: 39110661 No abstract available.

7

The current and future role of systemic therapy in non-muscle-invasive bladder cancer.

Lazarovich A, Sweis RF. Lazarovich A, et al. Among authors: sweis rf. Cancer. 2025 Jul 1;131(13):e35966. doi: 10.1002/cncr.35966. Cancer. 2025. PMID: 40581842 Free PMC article. Review.

8

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R. Sweis RF, et al. J Immunother Cancer. 2018 Apr 4;6(1):24. doi: 10.1186/s40425-018-0334-x. J Immunother Cancer. 2018. PMID: 29618376 Free PMC article.

9

T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Trujillo JA, Sweis RF, Bao R, Luke JJ. Trujillo JA, et al. Among authors: sweis rf. Cancer Immunol Res. 2018 Sep;6(9):990-1000. doi: 10.1158/2326-6066.CIR-18-0277. Cancer Immunol Res. 2018. PMID: 30181337 Free PMC article.

10

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.

Pearson AT, Sweis RF. Pearson AT, et al. Among authors: sweis rf. JAMA Oncol. 2019 May 1;5(5):743. doi: 10.1001/jamaoncol.2019.0130. JAMA Oncol. 2019. PMID: 30896751 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters